SCHEMBL63759

SCHEMBL63759

Cc1cc(C(=O)NC23CCC(CC2)Cn2c3nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)n(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.45
KCNH2 Q12809 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40
KCNE1 P15382 1/20 0.39
CCR1 P32246 1/20 0.39
KCNQ1 P51787 1/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ERCC1 P07992 1/20 0.35
FEN1 P39748 1/20 0.35
ERCC4 Q92889 1/20 0.35
TP53 P04637 2/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
LIPG Q9Y5X9 1/20 0.35
MMP13 P45452 1/20 0.34
CES2 O00748 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51547 0.88 KCNH2 (0.43) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL63360 0.88 KCNH2 (0.44) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL418372 0.86 KCNH2 (0.47) CYP2C9KCNH2SMN1; SMN2MAPTKCNE1
SCHEMBL52470 0.86 KCNH2 (0.49) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL52151 0.86 KCNH2 (0.44) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL64123 0.86 KCNH2 (0.44) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL52092 0.85 CYP2C9 (0.53) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL63760 0.85 KCNH2 (0.43) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL64134 0.85 KCNH2 (0.44) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL63407 0.85 CYP2C9 (0.46) CYP2C9KCNH2SMN1; SMN2MAPTKCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885KCNH2 3969/4885SMN1; SMN2 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.